POLIGLECAPRONE 25

Summary

Poliglecaprone 25 (CHEMBL2107968) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107968
Name	POLIGLECAPRONE 25
Type	Small molecule
Max phase	3

Also known as: Poliglecaprona, Poliglecaprone, Poliglecaprone 25, POLIGLECAPRONE 25

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01722565	PHASE4	COMPLETED	Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection
NCT02459093	PHASE4	COMPLETED	Subcuticular Suture for Cesarean Skin Incision Closure
NCT06543329	Not specified	NOT_YET_RECRUITING	Comparative Analysis of Subcuticular Suture Materials in Cesarean Section
NCT07569237	Not specified	NOT_YET_RECRUITING	Patient-Reported Outcomes of Four Intraoral Suture Materials
NCT00908661	Not specified	COMPLETED	Effectiveness of a Lightweight Mesh in the Laparoscopic Prevention of Parastomal Hernia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).